Importantly, “IGFBP3 Targeting Therapy” efficiently suppresses GBM invasion in vitro and tumor growth in vivo via reducing PD-L1 expression, suggesting that IGFBP3 may be a potential novel target for GBM therapy. Here, IGFBP3 is linked to neoplasm.